ArticleCureus2022
Capecitabine-Associated Coronary Vasospasm and Cardiac Arrest.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Case Report: Cardiotoxicity of capecitabine may manifest as STEMI with significant left ventricular cardiac dysfunction and recurrent supraventricular and ventricular arrhythmias: a proposal for optimal diagnosis and treatment.Frontiers in oncology · 2025Article
- Chemotherapy-related cardiotoxicity and its symptoms in patients with breast cancer: a scoping review.Systematic reviews · 2024Article
- Capecitabine-induced-coronary-vasospasm leading to polymorphic ventricular tachycardia and cardiac arrest.Cardio-oncology (London, England) · 2024Article
- Cardiotoxicity Induced by Capecitabine and Oxaliplatin in Gastric Cancer Treatment: A Rare Case of Cardiac Arrest and Cardiogenic Shock.European journal of case reports in internal medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Capecitabine is a prodrug of fluorouracil that specifically targets cancer cells, commonly used as monotherapy for metastatic breast and colorectal cancer. Its side effects include nausea, diarrhea, vomiting, abdominal pain, anorexia, palmar-plantar erythrodysesthesia, anemia, and hyperbilirubinemia. Rarely, this chemotherapy agent has been associated with cardiotoxicity, including cardiac arrest, likely secondary to coronary vasospasm. This case report serves to highlight the unfortunate case of a 32-year-old female who suffered a ventricular fibrillation cardiac arrest three days after initiating capecitabine therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.